Manchester Peptides catalogue profile
Retatrutide
An investigational triple receptor agonist designed to act on GLP-1, GIP and glucagon pathways. Researchers are studying how this combined signalling may affect appetite, glucose regulation, energy balance and body composition. It is not currently an approved UK medicine.
Available catalogue formats
Choose the listed format
Prices shown are the current catalogue guide prices.Vial · 30 mg
Retatrutide
Product information
An investigational triple receptor agonist designed to act on GLP-1, GIP and glucagon pathways. Researchers are studying how this combined signalling may affect appetite, glucose regulation, energy balance and body composition. It is not currently an approved UK medicine.
Evidence and sources at a glance
- Human evidence
- Randomised phase 2 evidence and reported phase 3 results are available. Check whether a particular result is a peer-reviewed publication or a sponsor announcement, and inspect its population and follow-up.
- Regulatory context
- Retatrutide is not currently an authorised UK medicine. Investigational status should never be presented as approval.
- Phase 2 obesity trial ↗Peer-reviewed randomised human trial indexed by PubMed.
- Lilly: current retatrutide programme ↗Sponsor overview, updated September 2026, linking reported phase 3 results and confirming investigational status. Sponsor material should be read alongside the underlying papers.
Pen · 40 mg
Retatrutide
Product information
An investigational triple receptor agonist designed to act on GLP-1, GIP and glucagon pathways. Researchers are studying how this combined signalling may affect appetite, glucose regulation, energy balance and body composition. It is not currently an approved UK medicine.
Evidence and sources at a glance
- Human evidence
- Randomised phase 2 evidence and reported phase 3 results are available. Check whether a particular result is a peer-reviewed publication or a sponsor announcement, and inspect its population and follow-up.
- Regulatory context
- Retatrutide is not currently an authorised UK medicine. Investigational status should never be presented as approval.
- Phase 2 obesity trial ↗Peer-reviewed randomised human trial indexed by PubMed.
- Lilly: current retatrutide programme ↗Sponsor overview, updated September 2026, linking reported phase 3 results and confirming investigational status. Sponsor material should be read alongside the underlying papers.
View supplied reference photograph
Plain-English identity
What is Retatrutide?
Researchers are studying whether activating all three pathways together can influence satiety, food intake, glucose control, energy expenditure and body composition more broadly than a single-pathway compound.
Phase 2 and reported phase 3 trials investigate weight and metabolic outcomes. Retatrutide remains investigational and is not an approved UK medicine; longer-term safety still matters.
Evidence and sources at a glance
- Human evidence
- Randomised phase 2 evidence and reported phase 3 results are available. Check whether a particular result is a peer-reviewed publication or a sponsor announcement, and inspect its population and follow-up.
- Regulatory context
- Retatrutide is not currently an authorised UK medicine. Investigational status should never be presented as approval.
- Phase 2 obesity trial ↗Peer-reviewed randomised human trial indexed by PubMed.
- Lilly: current retatrutide programme ↗Sponsor overview, updated September 2026, linking reported phase 3 results and confirming investigational status. Sponsor material should be read alongside the underlying papers.
Third-party documentation
Certificates of Analysis
Reference reports concern the named submitted samples. A catalogue batch match has not been established; check the strength and source on each report.Evidence-led research guide
Go deeper into Retatrutide
An investigational metabolic peptide designed to act on three hormone-receptor pathways involved in appetite, glucose regulation and energy balance.
Last reviewed 10 October 2026. Research and reference information only. This page does not provide dosing instructions, treatment recommendations or medical advice. Not for human or veterinary consumption.